ReWalk(US:LFWD)2026-03-18 12:15Revenue Performance - Lifeward reported a revenue of $5.1 million in Q4 2025, a decrease of approximately 33% from $7.5 million in Q4 2024[11]. - Revenue for the full year 2025 was $22.0 million, down 14% from $25.7 million in 2024[16]. - Lifeward reported revenue of $5,081,000 for Q4 2025, a decrease of 32.6% compared to $7,545,000 in Q4 2024[32]. - Total revenues for Q4 2025 were $5,081 million, a decrease of 32.6% from $7,545 million in Q4 2024[38]. - The company reported a total revenue of $22,034 million for the year ended December 31, 2025, down from $25,663 million in 2024[38]. Profitability and Loss - Lifeward's net loss narrowed by 65% to $5.3 million, or $3.60 per share, in Q4 2025, compared to a net loss of $15.3 million, or $20.82 per share, in Q4 2024[15]. - The company's net loss for Q4 2025 was $5,348,000, compared to a net loss of $15,278,000 in Q4 2024, representing a 65.0% improvement[32]. - GAAP net loss for Q4 2025 was $(5,348) million compared to $(15,278) million in Q4 2024, showing an improvement[38]. - Non-GAAP net loss per share for Q4 2025 was $(2.85), a decrease from $(4.54) in Q4 2024[38]. Operating Expenses - Total operating expenses in Q4 2025 declined by 64% to $6.2 million from $17.1 million in Q4 2024[13]. - Lifeward's total operating expenses for the full year 2025 decreased by 25% to $28.1 million from $37.6 million in 2024[18]. - Total operating expenses for Q4 2025 were $6,206,000, down from $17,072,000 in Q4 2024, indicating a reduction of 63.6%[32]. Cash and Assets - As of December 31, 2025, Lifeward had $2.2 million in unrestricted cash and cash equivalents[21]. - Cash and cash equivalents at the end of Q4 2025 were $2,169,000, down from $6,746,000 at the end of Q4 2024, a decline of 67.7%[34]. - Lifeward's total assets decreased to $22,900,000 as of December 31, 2025, from $30,487,000 in 2024, a decline of 25.0%[34]. - The company experienced a net cash used in operating activities of $16,826,000 for the year ended December 31, 2025, compared to $21,718,000 in 2024, a reduction of 22.6%[36]. Research and Development - Research and development expenses for the year ended December 31, 2025, were $3,249,000, a decrease of 29.8% from $4,625,000 in 2024[32]. - Research and development expenses for Q4 2025 were $843 million, which is 16.6% of revenue, compared to 15.0% in Q4 2024[40]. Strategic Initiatives - The company expects to close a strategic transaction with Oramed, which includes up to $47 million in additional funding, positioning Lifeward towards cash flow positive[4]. - Lifeward's acquisition of powered upper-body exoskeleton technology is expected to be ready for commercial launch within 18 to 24 months[5]. - The company expanded reimbursement coverage for the ReWalk Personal Exoskeleton, providing access to approximately 16 million covered lives in the U.S.[6]. Liabilities - Lifeward's total current liabilities increased to $12,039,000 as of December 31, 2025, from $10,225,000 in 2024, an increase of 17.8%[34]. Financial Guidance - The company did not provide GAAP reconciliation for its non-GAAP financial guidance due to uncertainties in predicting certain expenses[29].